Evidence map›Paper›PMID 39425118›Full record

ArticleBMC psychiatry2024

Effects of 6-week olanzapine treatment on serum IL-2, IL-4, IL-8, IL-10, and TNF-α levels in drug-naive individuals with first-episode schizophrenia.

Xiaofeng Zhao, Wenli Zhu, Yangying Bu, Junwei Li, Yihui Hao, Yuxiao Bi

Abstract read
In one paragraph

Article in BMC psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaofeng Zhao *Department of Psychiatry, First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450000, Henan, PR China. zxf0605004@163.com.
Wenli Zhu *Department of Psychiatry, the Fourth Hospital of Wuhu City, Wuxiashan East Road, Wuhu City, 241000, Anhui Province, PR China. 3081586616@qq.com.
Yangying Bu *Department of Psychiatry, the Fourth Hospital of Wuhu City, Wuxiashan East Road, Wuhu City, 241000, Anhui Province, PR China.
Junwei LiDepartment of Psychiatry, the Fourth Hospital of Wuhu City, Wuxiashan East Road, Wuhu City, 241000, Anhui Province, PR China.
Yihui HaoDepartment of Psychiatry, First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450000, Henan, PR China.
Yuxiao BiDepartment of Psychiatry, First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450000, Henan, PR China.

Funding

key scientific research project of higher education institutions in Henan Province 23A320045key scientific research project of higher education institutions in Henan Province 23A320058Scientific Research Project of Anhui Provincial Health Commission AHWJ2022b096the project of Anhui Science and Technology 202204295107020065the projects of Wuhu Science and Technology 2021jc2-3
6 · The paper itself

Abstract

backgroundSchizophrenia is a complex neuropsychiatric disorder. Growing evidence indicates that the activation of the inflammatory response system with interleukin (IL)-2, IL-4, IL-8, IL-10, and tumor necrosis factor-alpha (TNF-α) plays an important role in the pathogenesis of schizophrenia,. However, clinical data on cytokine levels in patients with schizophrenia treated with antipsychotics are inconsistent or inconclusive. In this study, we have examined inflammatory factors' alterations and their relationship to changes in clinical symptoms before and after olanzapine treatment of drug-naive patients with first-episode schizophrenia.

methodsWe recruited 142 hospitalized patients with first-episode schizophrenia as a study group; blood samples were collected, and the patients were assessed for clinical symptoms at baseline and after 6 weeks of olanzapine treatment. One hundred individuals with no history of mental illness were also recruited as healthy controls. Blood samples were collected, and the serum levels of IL-2, IL-4, IL-8, IL-10, and TNF-α were determined using an enzyme cycling assay. The severity of clinical symptoms was assessed according to the Positive and Negative Syndrome Scale (PANSS).

resultsIndividuals with schizophrenia had lower IL-8 levels and higher IL-10 levels than healthy controls (P < 0.001). Positive correlations were detected between serum IL-2 and IL-10 concentrations and each subscale of the PANSS (all P < 0.05). Moreover, a negative correlation existed between the serum IL-8 concentration and the PANSS negative score (r = - 0.172, P = 0.040). After 6 weeks of treatment, serum IL-8 levels in the patient group were lower than at baseline (P < 0.001), whereas serum IL-10 and TNF-α levels were higher than at baseline (all P < 0.05). Therefore, serum IL-10 can be determined as an independent risk factor for outcome in patients with first-episode schizophrenia (P = 0.02, OR = 2.327). Furthermore, serum IL-2, IL-10, and TNF-α levels were significantly lower, whereas the serum IL-8 level was significantly higher (P < 0.001) in the healthy control group than in the "response" and "no-response" treatment groups respectively.

conclusionsOur results indicate that serum IL-2, IL-8, IL-10, and TNF-α levels may be involved in the pathophysiological mechanisms of schizophrenia and correlate with the effects of olanzapine.

Indexed as

Antipsychotic AgentsInterleukin-10Interleukin-2OlanzapineSchizophreniaTumor Necrosis Factor-alphaAdultBenzodiazepinesFemaleHumansInterleukin-4Interleukin-8MaleYoung AdultAntipsychotic AgentsBenzodiazepinesIL10 protein, humanIL4 protein, humanInterleukin-10Interleukin-2Interleukin-4Interleukin-8OlanzapineTumor Necrosis Factor-alphaInterleukin-10Interleukin-2Interleukin-8SchizophreniaTumor necrosis factor-alpha

Identifiers

PMID39425118
PMCPMC11490170

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.